Etienna Bio, Inc., a biotechnology company focused on next-generation autologous and cell-enabled biomaterials for regenerative and aesthetic application...
Revvity, Inc. announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by ma...
Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LGC Gr...
Charles River Laboratories’ announcement of a planned leadership transition marks one of the most consequential succession moments in the global pr...
Sharp Sterile Manufacturing has announced a $28 million expansion of its site in Lee, Massachusetts. The enhanced state-of-the-art facility will st...
Akkermansia muciniphila postbiotic receives both U.S. FDA dietary supplement clearance and Korean functional ingredient approval with muscle health ...
Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, announced an agree...
- Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, ...
Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and de...
Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, announced a strategic collaboration with ...
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney dis...
Market participants appear to be adopting a wait and watch stance, with sentiment shaped less by near term fundamentals and more by expecta...
FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a fo...
Tiger BioSciences highlights a series of major clinical and scientific achievements resulting from the company's expanded investment in evidence‑based ...
© 2026 Biopharma Boardroom. All Rights Reserved.
